Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
Most drugs have some efficacy so that improved methods to determine the relative intrinsic efficacy of partial agonists should be of benefit to preclinical and clinical investigators. We examined the effects of partial D(1) or partial D(2) dopamine agonists using a partial agonist interaction model. The dependent variable was the modulation of the dopamine-receptor-mediated cAMP response in C6 glioma cells selectively and stably expressing either D(1) or D(2) recombinant dopamine receptors. The dissociation constant (K(B)) and relative intrinsic efficacy (E(r)) for each partial agonist were calculated using a partial agonist interaction null model in which the effects of fixed concentrations of each partial agonist on the dopamine dose-response curve were evaluated. This model is an extension of the competitive antagonist null model to drugs with efficacy and assumes only that the log-dose--response curve is monotonic. Generally, the partial agonist interaction model fit the data, as well as fits of the independent logistic curves. Furthermore, the partial agonist K(B) values could be shared across partial agonist concentrations without worsening the model fit (by increasing the residual variance). K(B) values were also similar to drug affinities reported in the literature. The model was validated in three ways. First, we assumed a common tissue stimulus parameter (beta) and calculated the E(r) values. This provided a qualitative check on the interaction model results. Second, we calculated new relative efficacy values, E(r)(beta), using the beta estimate. Third, we calculated relative efficacy using relative maxima times midpoint shift ratios (J. Theor. Biol. 198 (1999) 347.). All three methods indicated that the present model yielded reasonable estimates of affinity and relative efficacy for the set of compounds studied. Our results provide a quick and convenient method of quantification of partial agonist efficacy. Special applications and limitations of the model are discussed. In addition, the present results are the first report of the relative intrinsic efficacy values for this set of D(2) ligands.
Avalos
M
M
Institute for Neuroscience, University of Texas, Austin, TX 78712-1074, USA.
Mak
C
C
Randall
P K
PK
Trzeciakowski
J P
JP
Abell
C
C
Kwan
S W
SW
Wilcox
R E
RE
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D003024:Clozapine / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000737:chemistry / Q000145:classification / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000737:chemistry / Q000145:classification / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018818:Fenoldopam / Q000494:pharmacology; D005910:Glioma / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007700:Kinetics; D008090:Lisuride / Q000031:analogs & derivatives / Q000494:pharmacology; D015233:Models, Statistical; D009010:Monte Carlo Method; D017711:Nonlinear Dynamics; D000078183:Oxindoles; D011725:Pyridines / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D017447:Receptors, Dopamine D1 / Q000819:agonists* / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000378:metabolism; D013141:Spiro Compounds / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D001381:Azepines; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D007211:Indoles; D000078183:Oxindoles; D011725:Pyridines; D011804:Quinolines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D013141:Spiro Compounds; C006208:dironyl; C042709:tiospirone; C059613:roxindole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C024763:talipexole; D000242:Cyclic AMP; D008090:Lisuride; D018818:Fenoldopam; D003024:Clozapine; D006220:Haloperidol; D004298:Dopamine; C047726:quinelorane